Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Curvebeam AI Ltd. ( (AU:CVB) ).
CurveBeam AI has secured Chinese Outbound Direct Investment approval for the first A$4 million tranche of a strategic equity investment of up to A$10 million from Shandong WeiYing Intelligent Medical Technology, backed by leading orthopaedic device maker WEGO Orthopaedics, as part of a 10-year exclusive commercialisation deal for its weight-bearing CT and AI solutions across Greater China. Shares for the initial tranche will be issued at A$0.405, a substantial premium to CurveBeam AI’s recent trading price, with a further A$6 million available upon meeting agreed commercial and regulatory milestones, bolstering the company’s balance sheet and supporting regulatory, manufacturing and commercial expansion in China, Hong Kong, Macau and Taiwan, and providing a pathway to long-term revenue and royalty growth from a major international market.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is an ASX-listed medical technology company that develops, manufactures and sells specialised point-of-care CT imaging systems, notably its HiRise weight-bearing CT scanner, alongside AI-enabled SaaS clinical assessment tools for musculoskeletal care. The company employs more than 70 staff and operates from a corporate office in Melbourne, Australia, with global operations headquartered in Hatfield, Pennsylvania, targeting orthopedic and musculoskeletal imaging markets worldwide.
Average Trading Volume: 1,469,980
Technical Sentiment Signal: Sell
Current Market Cap: A$36.03M
Learn more about CVB stock on TipRanks’ Stock Analysis page.